Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C
Julien Vergniol, Jérôme Boursier, Clélia Coutzac, Sandrine Bertrais, Juliette Foucher, Camille Angel, Faiza Chermak, Isabelle Fouchard Hubert, Wassil Merrouche, Frédéric Oberti, Victor Lédinghen, Paul Calès – 12 February 2014 – No data are available about the prediction of long‐term survival using repeated noninvasive tests of liver fibrosis in chronic hepatitis C (CHC). We aimed to assess the prognostic value of 3‐year liver stiffness measurement (LSM), aspartate aminotransferase to platelet ratio index (APRI), and fibrosis 4 (FIB‐4) evolution in CHC.